Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
Last updated
89 sources

Economic information and modeling report

Modeling overview

3 evidence topics · 1 source

Summary

No product-specific comparative budget impact model was identified. The Dutch horizon scan estimates annual treatment cost at €100,000–500,000 per patient, expected annual patient volume below 100, and potential total annual expenditure of €30 million. These are prospective horizon-scan estimates. The page does not present comparator costs, treatment uptake over time, healthcare cost offsets, or scenario analyses that would establish incremental budget impact. The estimates do not establish a U.S. acquisition price or a U.S. payer-specific budget impact.

Prospective Dutch patient volume and total annual expenditure

Horizon-scan measureReported estimate
Expected patient volume per year“< 100”
Potential total cost per year“€ 30,000,000.00”